Insider · CIK 0002107268
Sherwin Sattarzadeh
Files at DMRA (Damora Therapeutics, Inc.). First filing -, latest -.
Sherwin Sattarzadeh files SEC Form 4 as COO at DMRA (Damora Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Sherwin Sattarzadeh has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | DMRA Damora Therapeutics, Inc. | AGrant or award Common Stock | +190,376 | $0.00 | $0 | 190,376 | Jan 26, 2026 |
| Jan 5, 2026 | DMRA Damora Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +444,209 | $0.00 | $0 | 444,209 | Jan 26, 2026 |
Questions about Sherwin Sattarzadeh
Answered from the filings on this page, as of the latest one.
Is Sherwin Sattarzadeh buying or selling?
Sherwin Sattarzadeh has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Sherwin Sattarzadeh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sherwin Sattarzadeh has 0.
Where does Sherwin Sattarzadeh file Form 4?
Sherwin Sattarzadeh has filed Form 4 at DMRA (Damora Therapeutics, Inc.) as Chief Operating Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.